CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma Journal Article

Authors: Smith, E.; Devlin, S. M.; Kosuri, S.; Orlando, E.; Landau, H.; Lesokhin, A. M.; Chung, D. J.; Hassoun, H.; Lendvai, N.; Landgren, O.; Giralt, S.; Chari, A.; Jagannath, S.; Koehne, G.
Article Title: CD34-selected allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma
Abstract: We report results of a retrospective analysis of 44 patients with relapsed and high-risk multiple myeloma (MM) undergoing allogeneic CD34-selected hematopoietic stem cell transplantation (HSCT) from HLA-compatible donors. Patients had multiply relapsed disease including relapse at <15 months after autologous transplantation and most patients (28 of 44; 65%) also had high-risk cytogenetics. Before transplantation, patients received busulfan (8 mg/kg × 10 doses), melphalan (70 mg/m2 × 2 days), fludarabine (25 mg/m2 × 5 days), and rabbit antithymocyte globulin (2.5 mg/kg × 2 days). Patients with 10/10 HLA- matched donors were treated prophylactically with low doses of donor lymphocyte infusions (5 to 1 × 106 CD3+/kg) starting 4 to 6 months after CD34-selected HSCT. Acute (grade II to IV) graft-versus-host disease (GVHD) and transplantation-related mortality at 12 months were 2% and 18%, respectively. Chronic GVHD was not observed in any patient. Overall and progression-free survival at 2 years were 54% and 31%, respectively. By multivariate analyses, the outcomes of CD34-selected HSCT were influenced by presence of extramedullary disease, disease status before CD34-selected HSCT, and age. This study demonstrates notable safety and efficacy of CD34-selected HSCT in patients with multiply relapsed MM, including those with high-risk cytogenetics. © 2016 American Society for Blood and Marrow Transplantation.
Keywords: adoptive immunotherapy; d34-selected hematopoietic stem cell transplantation; relapsed high-risk multiple myeloma
Journal Title: Biology of Blood and Marrow Transplantation
Volume: 22
Issue: 2
ISSN: 1083-8791
Publisher: Elsevier Inc.  
Date Published: 2016-02-01
Start Page: 258
End Page: 267
Language: English
DOI: 10.1016/j.bbmt.2015.08.025
PROVIDER: scopus
PUBMED: 26325439
PMCID: PMC4975432
Notes: Article -- Export Date: 3 March 2016 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Sergio Andres Giralt
    540 Giralt
  2. Hani Hassoun
    149 Hassoun
  3. Guenther Koehne
    175 Koehne
  4. Heather Jolie Landau
    189 Landau
  5. Nikoletta Lendvai
    87 Lendvai
  6. Alexander Meyer Lesokhin
    118 Lesokhin
  7. David Chung
    83 Chung
  8. Sean McCarthy Devlin
    307 Devlin
  9. Eric Smith
    36 Smith
  10. Carl Ola Landgren
    198 Landgren
  11. Satyajit   Kosuri
    23 Kosuri